RCI is Focusing on Some of the World’s Most Intractable Current
and Imminent Challenges
The world’s population is expected to grow by 1/3 between 2009 and 2050 to 9.1 billion people — creating additional
demand for safe and sustainably raised food. (Source: Food and Agriculture Organization of the United Nations).
Our Acceligen subsidiary leverages precision breeding to provide natural livestock disease resistance, improve food production and enhance animal welfare in beef, dairy, pork, poultry, and aquaculture production.
Millions of patients today are waiting for answers that will relieve their suffering, be it a new drug, a new medical device, or replacement of a diseased organ. In the U.S. alone, 22 people die every day waiting for an organ transplant.
The market opportunity:
RCI is poised to address these problems, and also tap into three massive markets for gene-edited food animals:
- Animal agriculture >$5 billion,
- Biomedical research >$2 billion and
- Regenerative medicine >$100 billion.
RCI’s dedicated subsidiaries, Acceligen, Surrogen and Regenevida, to tap into these markets.
We’re leading the way:
RCI has been an industry pioneer, having consistently achieved breakthroughs in gene editing and commercialization of its animal models. RCI outpaces its competitors in intellectual property, with 15 patents and more than 300 patent filings on gene-editing methods, traits, and novel reproduction methods in animals, and have achieved many industry “firsts”.
Our value proposition reflects compassion, drive and unique talents:
RCI was built upon sustainable and ethical practices to use gene-editing as a catalyst to provide real solutions to significant world problems.
Our reach is wide:
We’ve built a global customer base and worldwide partnerships.
Our location is strategic:
Headquartered in the Silicon Valley of Genetic Discovery and the Breadbasket of America,we’ve built strong relationships with the best-in-class in healthcare and food production. Minnesota is home to Mayo Clinic, United Health Group, University of Minnesota (one of the best public research institutions), Medtronic, St. Jude Medical, Cargill, General Mills and Hormel. Minnesota is also the #3 state in pork production.
Also important is our research facility near Madison, Wisconsin, under the leadership of one of the leading experts on animal reproduction.
Our leadership is unrivaled:
RCI’s business platforms continue to progress supported by its expert internal science team, proven executive team, and an array of noted advisors, partners and specialized staff.
The buzz is loud:
Gene editing is constantly making today’s news and RCI is often part of the story. Our experts are sought-after for news interviews, guest commentaries, speaking engagements and lectures.
For investor relations and to learn more, please contact:
Justin Zenanko, CPA
Senior Vice President of Corporate Development